Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial-Reference-Cited by-同舟云学术

Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial

Published:2017-09-01 Issue:3 Volume:32 Page:719-728
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Ailawadhi S,Mikhael J R,LaPlant B R,Laumann K M,Kumar S^ORCID,Roy V,Dingli D,Bergsagel P L,Buadi F K,Rajkumar S V,Fonseca R,Gertz M A,Kapoor P,Sher T,Hayman S R,Stewart A K,Dispenzieri A,Kyle R A,Gonsalves W I,Reeder C B,Lin Y,Go R S,Leung N,Kourelis T,Lust J A,Russell S J,Chanan-Khan A A,Lacy M Q

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2017258.pdf

Reference23 articles.

1. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015; 373: 621–631.

2. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372: 142–152.

3. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016; 375: 1319–1331.

4. Moreau P, Masszi T, Grazsko N, Bahlis NJ, Hansson M, Pour L et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016; 374: 1621–1634.

5. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016; 375: 754–766.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical efficacy of Thalidomide combined with PAD Regimen in patients with multiple Myeloma;Pakistan Journal of Medical Sciences;2023-07-10

2. Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review;Cancers;2021-05-31

3. Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study;Journal of Clinical Medicine;2021-04-05

4. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma;Blood Reviews;2020-05

5. Next-generation immunomodulatory drugs in multiple myeloma;Postępy Higieny i Medycyny Doświadczalnej;2019-12-31